CHARLES RIVER LABORATORIES INTERNATIONAL, INC. - Quarter Report: 2025 June (Form 10-Q)

See Notes to Unaudited Condensed Consolidated Financial Statements.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

(in thousands)

Three Months Ended

Six Months Ended

June 28, 2025

June 29, 2024

June 28, 2025

June 29, 2024

Net income

Other comprehensive income (loss):

Foreign currency translation adjustment

()

Amortization of net loss, settlement losses, and prior service benefit included in total cost for pension and other post-retirement benefit plans

Unrealized gains (losses) on hedging instruments

()

Other comprehensive income (loss), before income taxes

()

Less: Income tax expense (benefit) related to items of other comprehensive income

()

Comprehensive income, net of income taxes

Less: Comprehensive gain (loss) related to noncontrolling interests, net of income taxes

()

Comprehensive income attributable to Charles River Laboratories International, Inc., net of income taxes

Other, net Changes in assets and liabilities: Trade receivables and contract assets, net() Inventories() Accounts payable ()Accrued compensation ()Deferred revenue Customer contract deposits Other assets and liabilities, net()()Net cash provided by operating activities Cash flows relating to investing activities Capital expenditures()()Purchases of investments and contributions to venture capital investments()()Proceeds from sale of investments Proceeds from sale of businesses and assets, net Acquisition of businesses and assets, net of cash acquired ()Other, net ()Net cash used in investing activities()()Cash flows relating to financing activities Proceeds from long-term debt and revolving credit facility Payments on long-term debt, revolving credit facility, and finance lease obligations()()Proceeds from exercises of stock options Purchase of treasury stock()()Payments of contingent consideration() Purchase of remaining equity interest of other redeemable noncontrolling interests()()Other, net()()Net cash used in financing activities()()Effect of exchange rate changes on cash, cash equivalents, and restricted cash ()Net change in cash, cash equivalents, and restricted cash()()Cash, cash equivalents, and restricted cash, beginning of period Cash, cash equivalents, and restricted cash, end of period$ $

See Notes to Unaudited Condensed Consolidated Financial Statements.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS (UNAUDITED)

(in thousands)

)

Redeemable Noncontrolling Interests

Common Stock

Additional Paid-In Capital

Retained Earnings

Accumulated Other Comprehensive Income (Loss)

Treasury Stock

Total Charles River Laboratories, Inc. Equity

Noncontrolling Interest

Total Equity

Amount

December 28, 2024

()

Net income

—

Other comprehensive income (loss), net of tax

()

—

Adjustment of redeemable noncontrolling interests to redemption value

—

()

—

()

—

()

Issuance of stock under employee compensation plans

—

Purchase of treasury shares

—

()

—

()

Share repurchase excise tax

—

()

—

()

Stock-based compensation

—

March 29, 2025

()

Net income

()

—

Other comprehensive income, net of tax

—

Adjustment of redeemable noncontrolling interest to redemption value

—

()

—

()

—

()

Dividends to noncontrolling interests

()

—

Issuance of stock under employee compensation plans

—

Purchase of treasury shares

—

()

—

()

Stock-based compensation

—

June 28, 2025

()

Net provision expenses were $ million and $ million during the six months ended June 28, 2025 and June 29, 2024, respectively and include recoveries of balances previously written off, which are excluded from the table above.

Transaction Price Allocated to Future Performance Obligations

The Company discloses the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of June 28, 2025. Excluded from the disclosure is the value of unsatisfied performance obligations for contracts with an original expected length of one year or less, contracts for which revenue is recognized at the amount to which the Company has the right to invoice for services performed, and service revenue recognized in accordance with ASC 842, “Leases”. The aggregate amount of transaction price allocated to the remaining performance obligations for all open customer contracts as of June 28, 2025 was $ million. The Company will recognize revenues for these performance obligations as they are satisfied, approximately % of which is expected to occur within the next and the remainder recognized thereafter during the remaining contract term.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

million and $ million in lease revenue during the three months ended June 28, 2025 and June 29, 2024. The Company recognized $ million and $ million in lease revenue during the six months ended June 28, 2025 and June 29, 2024. Due to the nature of these arrangements and timing of the contractual lease term, the remaining revenue to be recognized related to these lease performance obligations is not material to the unaudited condensed consolidated financial statements.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

reportable segments: RMS, DSA, and Manufacturing. The reportable segments comprise the structure used by the Company’s Chief Executive Officer, who is the Chief Operating Decision Maker (CODM), to make key operating decisions and assess performance. These segments are strategic business units with differing products and services.

The Company’s CODM evaluates the segments operating performance based on operating income. Operating income is the measure of profit or loss regularly provided to and used by the CODM to assess performance and allocate resources. Operating income is defined as revenue less costs of revenue; selling, general, and administrative expenses; and amortization of intangible assets. For each segment, the CODM uses operating income in the annual budgeting and quarterly forecasting process when comparing to actual results. Asset information on a reportable segment basis is not disclosed as this information is not separately identified and internally reported to the Company’s CODM. The following table presents the results of operations by reportable segment:

$ $ $ Cost of revenue (excluding amortization of intangible assets) Selling, general and administrative Amortization of intangible assets Operating income$ $ $ $ DSARevenue$ $ $ $ Cost of revenue (excluding amortization of intangible assets) Selling, general and administrative Amortization of intangible assets Operating income$ $ $ $ ManufacturingRevenue$ $ $ $ Cost of revenue (excluding amortization of intangible assets) Selling, general and administrative Amortization of intangible assets Operating income$ $ $ $

Unallocated Corporate (1)

Selling, general and administrative$ $ $ $ Operating loss$()$()$()$()

(1) Operating income for unallocated corporate consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

$ $ $ DSA Manufacturing Total revenue$ $ $ $ Operating Income (Loss)RMS$ $ $ $ DSA Manufacturing Segment operating income Unallocated Corporate()()()()Operating income$ $ $ $ Other income (expense):Interest income Interest expense()()()()Other income (expense), net ()() Income before income taxes$ $ $ $

Capital expenditures and depreciation and amortization (related to both intangible assets and certain assets acquired in business combinations) by reportable segment are as follows:

RMS

DSA

Manufacturing

Unallocated Corporate

Consolidated

(in thousands)

Capital Expenditures

Three Months Ended:

June 28, 2025

June 29, 2024

Six Months Ended:

June 28, 2025

June 29, 2024

Depreciation and amortization (1)

Three Months Ended:

June 28, 2025

June 29, 2024

Six Months Ended:

June 28, 2025

June 29, 2024

(1) Depreciation and amortization includes both inventory step up amortization expense and biological assets amortization expense.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

$ $ $ $ $ June 29, 2024 Six Months Ended:June 28, 2025$ $ $ $ $ $ June 29, 2024

(1) The Other category represents operations located in Brazil, Israel, and Mauritius.

Long-lived assets consist of property, plant, and equipment, net.

$ $ $ $ $ December 28, 2024

Foreign currency translation ()Ending balance$ $

$ $ $ Total assets measured at fair value$ $ $ $ Accrued liabilities measured at fair value:Contingent consideration$ $ $ $ Total liabilities measured at fair value$ $ $ $

The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the six months ended June 28, 2025, there were no transfers between levels.

$ $ $ Other assets:Life insurance policies Total assets measured at fair value$ $ $ $ Accrued liabilities measured at fair value:Contingent consideration$ $ $ $ Other long-term liabilities measured at fair valueContingent consideration$ $ $ $ Total liabilities measured at fair value$ $ $ $

During the year ended December 28, 2024, there were no transfers between levels.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

$ Payments() Adjustment of previously recorded contingent liability Ending balance$ $

The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, which incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The unobservable inputs used in the fair value measurements include the probabilities of successful achievement of certain financial targets, forecasted results or targets, volatility, and discount rates. The remaining maximum potential payments are approximately $ million, of which the value accrued as of June 28, 2025 is $ million as the probability of achieving the maximum target is estimated to be %. The volatility and weighted average cost of capital is approximately % and %, respectively. Increases or decreases in these assumptions may result in a higher or lower fair value measurement, respectively.

Debt Instruments

The book value of the Company’s revolving loans are variable rate loans carried at amortized cost which approximates the fair value. The fair value is based on significant other observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2 within the fair value hierarchy.

The book value of the Company’s Senior Notes are fixed rate obligations carried at amortized cost. Fair value is based on quoted market prices as well as borrowing rates available to the Company. As the fair value is based on significant other observable outputs, it is deemed to be Level 2 within the fair value hierarchy. The book value, excluding issuance costs, and fair value of the Company’s Senior Notes is summarized below:

% Senior Notes due 2028$ $ $ $

% Senior Notes due 2029

% Senior Notes due 2031

$ $ $ Divestitures () ()Foreign exchange June 28, 2025$ $ $ $

(1) DSA includes accumulated impairment losses of $ billion, which were recognized in fiscal years 2008 and 2010.

(2) Manufacturing includes an accumulated impairment loss of $ million, which was recognized in fiscal year 2024.

As of the beginning of fiscal 2025, the Company has combined the Discovery Services and Safety Assessment reporting units into a single reporting unit consistent with recent changes to the DSA integrated operating structure.

The increase in goodwill during the six months ended June 28, 2025 is primarily related to the effect of foreign exchange; partially offset by a divestiture of a site in the DSA reportable segment.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

$()$ $ $()$ Technology () () Trademarks and trade names () () ()

Redeemable Noncontrolling Interests

The Company has held and continues to hold redeemable noncontrolling interests. Since the Company has the right to purchase, and the noncontrolling interest holders have the right to require the Company to purchase the remaining interest, which represents a derivative embedded within the equity instrument, the noncontrolling interest is classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities.

The redeemable noncontrolling interests are measured at the greater of (i) the redemption amount or (ii) the historical value resulting from the original acquisition date fair value, increased or decreased for the noncontrolling interest’s share of net income (loss), equity capital contributions and distributions. The fair value of the redeemable noncontrolling interest is determined using the income approach, with key assumptions being projected cash flows and discount rates based on market participant’s weighted average cost of capital. To the extent redemption value exceeds carrying value, adjustments are recorded to additional paid-in capital, with any cumulative excess of redemption value over fair value recorded in retained earnings, which impacts net income available to common shareholders used in the calculation of earnings per common share.

Noveprim

The Company holds a % ownership interest in Noveprim. The Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining % equity interest at a fixed redemption value that ranges from $ million to $ million depending on when exercised. The Company has the call option right to purchase the remaining % equity up until one month after the sixth anniversary of closing the % equity stake (December 2029). On the first anniversary of the expiration of the call option (December 2030), a 12-month put option will be triggered giving the seller the right to require the Company to acquire the remaining shares of the seller for $ million. Additionally, during fiscal year 2024 the % noncontrolling interest holders were eligible to receive a dividend disproportionate to their equity ownership, of which the fair value of $ million as of the acquisition date was recorded within the redeemable noncontrolling interest. The redemption value is accreted to the put purchase price of $ million using the interest method through December 2030. As of June 28, 2025, the redemption value of $ million exceeded the carrying value, resulting in an adjustment to additional paid in capital of $ million for the six months ended June 28, 2025. As of June 29, 2024, the redemption value of $ million exceeded both the carrying value and fair value, resulting in both an adjustment to additional paid in capital of $ million and an adjustment to retained earnings of $ million, respectively.

Other redeemable noncontrolling interest

In 2019, the Company acquired an % equity interest in a subsidiary, which included a % redeemable noncontrolling interest. In June 2022, the Company purchased an additional % interest in the subsidiary for $ million, resulting in a remaining noncontrolling interest of %. Beginning in 2024, the Company had the right to purchase, and the noncontrolling interest holders had the right to sell, the remaining % equity interest at its appraised value. The redemption value was measured at the greater of the appraised value or a predetermined floor. The amount that the Company could be required to pay to purchase the remaining % equity interest was not limited. As of March 30, 2024, the redemption value of $ million exceeded the carrying value, resulting in an adjustment to additional paid in capital of $ million. During the second quarter of fiscal 2024, the Company acquired the remaining % for $ million.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

% ownership interest in Vital River, a commercial provider of research models and related services in China as of December 31, 2022. The Company had the right to purchase, and the noncontrolling interest holders had the right to sell, the remaining % equity interest at a contractually defined redemption value, subject to a redemption floor. The amount that the Company could be required to pay to purchase the remaining % equity interest was not limited. During fiscal year 2023, the Company acquired the remaining % for a total sale amount of $ million. The remaining purchase price payable of $ million was included in Accrued liabilities within the Company’s consolidated balance sheet as of December 28, 2024 and was paid during the first quarter of fiscal 2025.

Nonredeemable Noncontrolling Interest

12.

% and %, respectively. The Company’s effective tax rates for the six months ended June 28, 2025 and June 29, 2024 were % and %, respectively. The increase in the effective tax rate for both the three and six months ended June 28, 2025 compared to the corresponding prior year periods were primarily attributable to the tax effects from stock-based compensation deductions, as well as non-taxable remeasurement gains on a previous equity investment in Noveprim during the three months ended June 29, 2024.

For the three months ended June 28, 2025, the Company’s unrecognized tax benefits increased by $ million to $ million, primarily due to increases in research and development tax credit reserves, as well as unfavorable foreign exchange movement. For the three months ended June 28, 2025, the amount of unrecognized income tax benefits that would impact the effective tax rate increased by $ million to $ million for the same reasons discussed above. The accrued interest on unrecognized tax benefits was $ million as of June 28, 2025. The Company estimates that it is reasonably possible that the unrecognized tax benefits will decrease by approximately $ million over the next twelve-month period, primarily due to audit settlements and expiring statutes of limitations.

$ Other current assetsAccrued income taxes Other current liabilities

The Company conducts business in a number of tax jurisdictions. As a result, it is subject to tax audits on a regular basis including, but not limited to, such major jurisdictions as the U.S., the U.K., China, France, Germany, and Canada. With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 2021.

On July 4, 2025, the U.S. enacted the One Big Beautiful Bill Act ("OBBBA"), which includes several changes to U.S. federal income tax law, including accelerated tax depreciation, expensing of research and development, and the U.S. international inclusions. The Company is assessing these impacts on its consolidated financial statements, but anticipates an impact to our deferred tax and cash tax positions relating to bonus depreciation and full expensing of domestic research and experimental expenditures. While the Company continues to assess the impact of the tax provisions of the OBBBA on its consolidated financial statements, the Company currently believes that the tax provisions of the legislation are not expected to have a material impact on the Company’s statement of operations.

The Company and certain of its subsidiaries have ongoing tax controversies in the U.S., Canada, France, Ireland, and India. The Company does not anticipate resolution of these audits will have a material impact on its unaudited condensed consolidated financial statements.

13.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

$ $ $ DSA Manufacturing Unallocated corporate Total$ $ $ $

The following table presents restructuring costs as included within the Company’s unaudited condensed consolidated statements of income:

June 28, 2025

June 29, 2024

Severance and Transition Costs

Asset Impairments and Other Costs

Total

Severance and Transition Costs

Asset Impairments and Other Costs

Total

(in thousands)

Three Months Ended

Cost of services provided (excluding amortization of intangible assets)

()

Cost of products sold (excluding amortization of intangible assets)

()

Selling, general and administrative

Total restructuring costs

Six Months Ended

Cost of services provided (excluding amortization of intangible assets)

Cost of products sold (excluding amortization of intangible assets)

Selling, general and administrative

Total restructuring costs

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

$ $ $

Expense

Payments / utilization

() ()()

Other non-cash adjustments

()()()

Foreign currency adjustments

Ending Balance

$ $ $ $ Six Months Ended June 29, 2024

Beginning balance

$ $ $ $

Expense

Payments / utilization

() ()()

Other non-cash adjustments

()()()

Foreign currency adjustments

() ()

Ending Balance

$ $ $ $

million and $ million, respectively, of severance and other personnel related costs liabilities were included in accrued compensation and accrued liabilities within the Company’s unaudited condensed consolidated balance sheets.

14.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for fiscal year 2024 as filed with the SEC on February 19, 2025. The following discussion contains forward-looking statements. Actual results may differ significantly from those projected in the forward-looking statements. Factors that might cause future results to differ materially from those projected in the forward-looking statements include, but are not limited to, those discussed in Item 1A, “Risk Factors” included elsewhere within this Form 10-Q. Certain percentage changes may not recalculate due to rounding.

Overview

We are a leading, full service, non-clinical global drug development partner. For over 75 years, we have been in the business of providing the research models required in the research and development of new drugs, devices, and therapies. Over this time, we have built upon our original core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports our clients from target identification through non-clinical development. We also provide a suite of products and services to support our clients’ manufacturing activities. Utilizing our broad portfolio of products and services enables our clients to create a more efficient and flexible drug development model, which reduces their costs, enhances their productivity and effectiveness, and increases speed to market.

Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world.

Segment Reporting

Our three reportable segments are Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Our RMS reportable segment includes the products and services offered within Research Models, Research Model Services, and Cell Solutions. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Insourcing Solutions (IS), which provides colony management of our clients’ research operations (including recruitment, training, staffing, and management services) within our clients’ facilities as well as our own vivarium space, utilizing our Charles River Accelerator and Development Lab (CRADL™) offerings, Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models; and Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Cell Solutions which provides controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow as well as cells from disease state donors.

Our DSA segment is comprised of Discovery and Safety Assessment services. We provide regulated and non-regulated DSA services to support the discovery, development, and regulatory-required safety testing of potential new drugs, including in vitro (non-animal) and in vivo (in research models) studies, laboratory support services, including bioanalytical and strategic non-clinical consulting and program management to support product development.

Our Manufacturing reportable segment includes Microbial Solutions, which provides in vitro lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO).

Fiscal Quarters

Our fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end.

U.S. Government Investigations into the Non-Human Primate Supply Chain

On February 17, 2023, we received a grand jury subpoena requesting certain documents related to an investigation by the U.S. Department of Justice (DOJ) and the U.S. Fish and Wildlife Service (USFWS) into our conduct regarding several shipments of non-human primates from Cambodia in late 2022 and early 2023 (the NHP Shipments). The DOJ also undertook a parallel civil investigation related to the NHP Shipments. As previously disclosed, we continued to care for the NHP Shipments during the pendency of the DOJ investigations. In July 2025, we were informed that USFWS had determined to clear the NHP Shipments

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

for legal entry into the United States. Furthermore, in recent weeks we have been advised by the DOJ that both the grand jury investigation and the parallel civil investigation had been closed.

On May 16, 2023, we received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting us to voluntarily provide information, subsequently augmented with a document subpoena and additional inquiries, primarily related to the sourcing of non-human primates and related disclosures, and we are cooperating with the requests. Our Audit Committee has retained counsel to conduct an independent investigation into certain issues raised in the investigations, and that work is ongoing. We are not able to predict what action, if any, might be taken in the future by the SEC. The SEC has not provided us with any specific timeline or indication as to when the investigation will be concluded or resolved. We cannot predict the timing, outcome or possible impact of the investigation, including without limitation any potential fines, penalties or liabilities.

Recent Government Actions

On July 4, 2025, the U.S. enacted the One Big Beautiful Bill Act (“OBBBA”), which includes changes to a broad range of tax reform provisions including accelerated tax depreciation, expensing of research and development, and the U.S. international inclusions. As a result of the enactment of the OBBBA, we anticipate an impact to our deferred tax and cash tax positions relating to bonus depreciation and full expensing of domestic research and experimental expenditures. We do not expect any material change to our ongoing effective tax rate as a result of this legislation.

In February 2025 the U.S. government announced plans to enact increased tariffs on Canada, China and Mexico, later broadening the increase to various countries within Europe, Africa and Asia. Subsequently, in April 2025, the U.S. formalized actions to delay the effective date of certain tariffs. As of the date of this report, a number of new tariffs remain in effect, including tariffs between the U.S., and countries from which we obtain significant supply, such as Vietnam, Mauritius and China. The extent and duration of these tariffs and the resulting impact on macroeconomic conditions and our business are uncertain and may depend on various factors including, but not limited to, negotiations between the U.S. and affected countries, reciprocal or retaliatory actions imposed by other countries, tariff exemptions, negative sentiment toward U.S. companies and products, and the availability of lower cost inputs that may be sourced domestically. While we plan to offset most of the estimated tariffs by passing along these higher costs, we will continue to evaluate the nature and extent of the impacts to our business and our operating results.

In April 2025, the U.S. Food and Drug Administration (FDA) announced plans to launch a pilot program to reduce animal testing in preclinical safety studies with scientifically validated cell-based and new approach methodologies (NAMs), such as organ-on-a-chip systems, computational modeling, and advanced in vitro assays. We support the FDA’s announcement as we believe the program aligns with the vision previously outlined in the FDA Modernization Act 2.0 and aims to develop a clearer regulatory pathway to streamline the drug development process and safely advance innovative technologies, including alternatives to the current animal based development process. As a leader in preclinical drug development, this vision is consistent with our long-standing mission to drive greater efficiency in the drug development process, enhance scientific innovation, and promote the responsible use of animals in biomedical research. We are continuously evaluating innovative approaches in drug development and have invested in virtual control groups for safety assessment studies and partnerships utilizing AI technologies to reduce animal use. Further, in April 2024, we launched our own Alternative Methods Advancement Project (AMAP), which is an initiative dedicated to developing alternatives to the use of animal testing within the drug development process. We remain committed to continuing to collaborate with regulatory agencies, including the FDA, the biopharmaceutical industry and other stakeholders, to help develop, validate, and implement an efficient process for our clients’ regulatory submissions that support the use of new, non-animal based technologies.

Global Market Environment

We are continuing to see a cautious spending environment from our client base, principally within our DSA segment related to our global biopharmaceutical and biotechnology clients, as they reassess their budgets, reprioritize their drug pipelines, and manage their cost structures. As we continue to navigate these challenges in the current macroeconomic environment, DSA backlog declined slightly to $1.9 billion as of June 28, 2025 from $2.0 billion as of December 28, 2024.

In response to recent trends observed across each of our businesses in the global market environment, we have undertaken and will continue to implement restructuring actions at various locations across North America, Europe and Asia. This includes workforce right-sizing actions, resulting in severance and transition costs; and costs related to the consolidation of facilities to optimize our global footprint and drive greater operating efficiency across the company, resulting in asset impairment, accelerated depreciation, and other site consolidation charges. During fiscal year 2023, we began taking restructuring actions as a result of these emerging business trends. We incurred restructuring charges of $32.2 million and $56.0 million, during the three and six months ended June 28, 2025, respectively, and $107.0 million and $29.7 million during fiscal 2024 and fiscal 2023, respectively. We expect that these effectuated actions, as well as other upcoming planned actions designed to optimize our global footprint to drive greater operating efficiency, will result in approximately $225 million of cost savings on an annualized basis, of which approximately $175 million will impact fiscal year 2025.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Results of Operations

Consolidated Results of Operations and Liquidity

Revenue for three months ended June 28, 2025 increased $6.0 million, or 0.6%, to $1,032.1 million compared to $1,026.1 million in the corresponding period in 2024. Revenue for six months ended June 28, 2025 decreased $21.4 million, or 1.0%, to $2,016.3 million compared to $2,037.7 million in the corresponding period in 2024. The increase in revenue for the three months ended June 28, 2025 was primarily attributable to our Manufacturing and RMS businesses driven by demand, partially offset by declines in our DSA business, which experienced lower volume driven by continued cautious client spending as a result of the demand environment when compared to the corresponding period in 2024. The decrease in revenue for the six months ended June 28, 2025 was driven by declines in our DSA business driven by the same market dynamics discussed above when compared to the corresponding period in 2024.

For the three months ended June 28, 2025, our operating income and operating income as a percentage of revenue were $100.1 million and 9.7% respectively, compared to $151.7 million and 14.8% respectively, in the corresponding period of 2024. For the six months ended June 28, 2025, our operating income and operating income as a percentage of revenue were $174.8 million and 8.7% respectively, compared to $277.6 million and 13.6% respectively, in the corresponding period of 2024. The decreases in operating income and operating income as a percentage of revenue for the three and six months ended June 28, 2025 were primarily driven by the acceleration of amortization expense recognized as a result of a decrease in the remaining useful life of certain CDMO client relationships due to a loss of key customers, restructuring activities, including higher asset impairments and site consolidation charges, and higher third-party legal costs and advisory costs when compared to the corresponding period in 2024.

Net income available to Charles River Laboratories International, Inc., common shareholders decreased to $52.3 million in the three months ended June 28, 2025, from $90.0 million in the corresponding period of 2024. Net income available to Charles River Laboratories International, Inc., common shareholders decreased to $77.8 million in the six months ended June 28, 2025, from $157.3 million in the corresponding period of 2024. The decreases in net income available to common shareholders were due principally to the decreases in operating income described above.

During the six months ended June 28, 2025, our cash flows from operations were $376.3 million compared with $323.4 million for the same period in 2024. The increase was primarily driven by lower payments of variable compensation and favorable timing of payments to our suppliers and vendors, partially offset by higher purchases of inventory to support our DSA reportable segment.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Three Months Ended June 28, 2025 Compared to the Three Months Ended June 29, 2024

Revenue and Operating Income

The following tables present consolidated revenue by type and by reportable segment:


	Three Months Ended
	June 28, 2025		June 29, 2024		$ change		% change
	(in thousands, except percentages)
Service revenue	$	840,836	$	842,900	$	(2,064)	(0.2)	%
Product revenue	191,299		183,217		8,082		4.4	%
Total revenue	$	1,032,135	$	1,026,117	$	6,018	0.6	%


	Three Months Ended
	June 28, 2025		June 29, 2024		$ change		% change		Impact of FX
	(in thousands, except percentages)
RMS	$	213,271	$	206,389	$	6,882	3.3	%	1.0	%
DSA	618,029		627,419		(9,390)		(1.5)	%	1.1	%
Manufacturing	200,835		192,309		8,526		4.4	%	1.5	%
Total revenue	$	1,032,135	$	1,026,117	$	6,018	0.6	%	1.2	%

The following table presents operating income by reportable segment:


	Three Months Ended
	June 28, 2025			June 29, 2024			$ change		% change		Impact of FX
	(in thousands, except percentages)
RMS	$	35,786		$	29,948		$	5,838	19.5	%	2.5	%
DSA	122,781			138,376			(15,595)		(11.3)	%	1.1	%
Manufacturing	12,061			37,230			(25,169)		(67.6)	%	0.5	%
Unallocated corporate	(70,494)			(53,902)			(16,592)		30.8	%	0.7	%
Total operating income	$	100,134		$	151,652		$	(51,518)	(34.0)	%	1.3	%
Operating income % of revenue	9.7		%	14.8		%			(510) bps

The following presents and discusses our consolidated financial results by each of our reportable segments:

RMS


	Three Months Ended
	June 28, 2025			June 29, 2024			$ change		% change		Impact of FX
	(in thousands, except percentages)
Revenue	$	213,271		$	206,389		$	6,882	3.3	%	1.0	%
Cost of revenue (excluding amortization of intangible assets)	143,135			142,942			193		0.1	%
Selling, general and administrative	28,369			27,597			772		2.8	%
Amortization of intangible assets	5,981			5,902			79		1.3	%
Operating income	$	35,786		$	29,948		$	5,838	19.5	%	2.5	%
Operating income % of revenue	16.8		%	14.5		%			230 bps

RMS revenue increased $6.9 million primarily driven by an increase in large research model product revenue, notably within China and from Noveprim, an increase in Insourcing Solutions and GEMS service revenue, and the effect of changes in foreign currency exchange rates; partially offset by a decline in Cell Solutions product revenue.

RMS operating income increased $5.8 million compared to the corresponding period in 2024. RMS operating income as a percentage of revenue for the three months ended June 28, 2025 was 16.8%, an increase of 230 bps from 14.5% for the corresponding period in 2024. Operating income and operating income as a percentage of revenue increased primarily due to the increase in revenue described above coupled with lower asset impairment charges related to recent restructuring activities compared to the corresponding period in 2024.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

DSA


	Three Months Ended
	June 28, 2025			June 29, 2024			$ change		% change		Impact of FX
	(in thousands, except percentages)
Revenue	$	618,029		$	627,419		$	(9,390)	(1.5)	%	1.1	%
Cost of revenue (excluding amortization of intangible assets)	421,907			418,964			2,943		0.7	%
Selling, general and administrative	60,270			54,479			5,791		10.6	%
Amortization of intangible assets	13,071			15,600			(2,529)		(16.2)	%
Operating income	$	122,781		$	138,376		$	(15,595)	(11.3)	%	1.1	%
Operating income % of revenue	19.9		%	22.1		%			(220) bps

DSA revenue decreased $9.4 million primarily due to lower volume driven by continued cautious client spending as a result of the current demand environment; partially offset by increases in pricing of offerings and the effect of changes in foreign currency exchange rates compared to the corresponding period in 2024.

DSA operating income decreased $15.6 million during the three months ended June 28, 2025 compared to the corresponding period in 2024. DSA operating income as a percentage of revenue for the three months ended June 28, 2025 was 19.9%, a decrease of 220 bps from 22.1% for the corresponding period in 2024. Operating income and operating income as a percentage of revenue decreased primarily due to the lower revenue described above, restructuring activities including site consolidation and asset impairment charges, and certain third-party legal and advisory costs incurred in connection with the investigations by the U.S. government into the non-human primate supply chain, compared to the corresponding period in 2024.

Manufacturing


	Three Months Ended
	June 28, 2025			June 29, 2024			$ change		% change		Impact of FX
	(in thousands, except percentages)
Revenue	$	200,835		$	192,309		$	8,526	4.4	%	1.5	%
Cost of revenue (excluding amortization of intangible assets)	110,026			110,498			(472)		(0.4)	%
Selling, general and administrative	32,416			33,813			(1,397)		(4.1)	%
Amortization of intangible assets	46,332			10,768			35,564		330.3	%
Operating income	$	12,061		$	37,230		$	(25,169)	(67.6)	%	0.5%
Operating income % of revenue	6.0		%	19.4		%			(1,340) bps

Manufacturing revenue increased $8.5 million primarily due to increased revenue in our Microbial Solutions business, driven by an increase in identification services revenue and endotoxin product revenue and the effect of changes in foreign currency exchange rate; partially offset by lower revenue for Biologics Testing services.

Manufacturing operating income decreased $25.2 million during the three months ended June 28, 2025 compared to the corresponding period in 2024. Manufacturing operating income as a percentage of revenue for the three months ended June 28, 2025 was 6.0%, a decrease of (1,340) bps from 19.4% for the corresponding period in 2024. Operating income and operating income as a percentage of revenue decreased primarily due to accelerated amortization expense as a result of a decrease in the remaining useful life of certain client relationships due to a loss of key customers within the CDMO business, and restructuring activities, including asset impairments and site consolidation charges, compared to the corresponding period in 2024; partially offset by the higher revenue described above.

Unallocated Corporate


	Three Months Ended
	June 28, 2025			June 29, 2024			$ change		% change		Impact of FX
	(in thousands, except percentages)
Unallocated corporate	$	70,494		$	53,902		$	16,592	30.8	%	0.7	%
Unallocated corporate % of revenue	6.8		%	5.3		%			150 bps

Unallocated corporate costs consist of selling, general and administrative expenses that are not directly related or allocated to the reportable segments. The increase in unallocated corporate costs of $16.6 million, or 30.8%, compared to the corresponding

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

period in 2024 is primarily due to higher third-party legal and advisory costs incurred in connection with execution of a Cooperation Agreement entered into with a shareholder earlier this year and higher variable compensation costs. Costs as a percentage of revenue for the three months ended June 28, 2025 was 6.8%, an increase of 150 bps from 5.3% for the corresponding period in 2024.

Other Income (Expense)


	Three Months Ended
	June 28, 2025		June 29, 2024		$ change		% change
	(in thousands, except percentages)
Other income (expense):
Interest income	$	1,097	$	3,010	$	(1,913)	(63.6)	%
Interest expense	(29,967)		(32,769)		2,802		(8.6)	%
Other income (expense), net	154		(2,240)		2,394		(106.9)	%
Total other expense, net	$	(28,716)	$	(31,999)	$	3,283	(10.3)	%

Interest income for the three months ended June 28, 2025 was $1.1 million, a decrease of $1.9 million, or 63.6%, driven primarily from lower interest rates and interest earning asset balances.

Interest expense for the three months ended June 28, 2025 was $30.0 million, a decrease of $2.8 million, or 8.6%, compared to $32.8 million in the corresponding period in 2024 due primarily to lower average debt balances.

Other income, net for the three months ended June 28, 2025 was $0.2 million compared to Other expense, net of $2.2 million for the corresponding period in 2024 due primarily to higher net gains on our life insurance contracts coupled with lower net losses on our investments compared to the corresponding period in 2024.

Income Taxes


	Three Months Ended
	June 28, 2025			June 29, 2024			$ change		% change
	(in thousands, except percentages)
Provision for income taxes	$	18,725		$	25,392		$	(6,667)	(26.3)	%
Effective tax rate	26.2		%	21.2		%			500 bps

Income tax expense for the three months ended June 28, 2025 was $18.7 million, a decrease of $6.7 million compared to $25.4 million for the corresponding period in 2024. Our effective tax rate was 26.2% for the three months ended June 28, 2025 compared to 21.2% for the corresponding period in 2024. The tax rate increase was primarily attributable to the tax effects from stock-based compensation deductions, as well as non-taxable remeasurement gains on a previous equity investment in Noveprim during the three months ended June 29, 2024.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Six Months Ended June 28, 2025 Compared to Six Months Ended June 29, 2024

Revenue and Operating Income

The following tables present consolidated revenue by type and by reportable segment:


	Six Months Ended
	June 28, 2025		June 29, 2024		$ change		% change
	(in thousands, except percentages)
Service revenue	$	1,638,759	$	1,659,762	$	(21,003)	(1.3)	%
Product revenue	377,544		377,915		(371)		(0.1)	%
Total revenue	$	2,016,303	$	2,037,677	$	(21,374)	(1.0)	%


	Six Months Ended
	June 28, 2025		June 29, 2024		$ change		% change		Impact of FX
	(in thousands, except percentages)
RMS	$	426,344	$	427,296	$	(952)	(0.2)	%	—	%
DSA	1,210,638		1,232,871		(22,233)		(1.8)	%	0.2	%
Manufacturing	379,321		377,510		1,811		0.5	%	0.1	%
Total revenue	$	2,016,303	$	2,037,677	$	(21,374)	(1.0)	%	0.2	%

The following table presents operating income by reportable segment:


	Six Months Ended
	June 28, 2025			June 29, 2024			$ change		% change		Impact of FX
	(in thousands, except percentages)
RMS	$	79,391		$	73,097		$	6,294	8.6	%	(0.2)	%
DSA	216,733			253,215			(36,482)		(14.4)	%	1.9	%
Manufacturing	3,441			70,911			(67,470)		(95.1)	%	(0.3)	%
Unallocated corporate	(124,762)			(119,594)			(5,168)		4.3	%	0.1	%
Total operating income	$	174,803		$	277,629		$	(102,826)	(37.0)	%	1.6	%
Operating income % of revenue	8.7		%	13.6		%			(490) bps

The following presents and discusses our consolidated financial results by each of our reportable segments:

RMS


	Six Months Ended
	June 28, 2025			June 29, 2024			$ change		% change		Impact of FX
	(in thousands, except percentages)
Revenue	$	426,344		$	427,296		$	(952)	(0.2)	%	—	%
Cost of revenue (excluding amortization of intangible assets)	282,431			283,867			(1,436)		(0.5)	%
Selling, general and administrative	52,575			58,490			(5,915)		(10.1)	%
Amortization of intangible assets	11,947			11,842			105		0.9	%
Operating income	$	79,391		$	73,097		$	6,294	8.6	%	(0.2)	%
Operating income % of revenue	18.6		%	17.1		%			150 bps

RMS revenue decreased $1.0 million primarily driven by lower Cell Solutions product revenue and large research model product revenue due to timing of sales; partially offset by an increase in small research models product revenues principally due to price.

RMS operating income increased $6.3 million compared to the corresponding period in 2024. RMS operating income as a percentage of revenue for the six months ended June 28, 2025 was 18.6%, an increase of 150 bps from 17.1% for the corresponding period in 2024. Operating income and operating income as a percentage of revenue increased primarily due to lower charges related to restructuring activities, including asset impairments and site consolidation charges; partially offset by higher amortization related to acquisitions and the impacts of the RMS revenue drivers described above compared to the corresponding period in 2024.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

DSA


	Six Months Ended
	June 28, 2025			June 29, 2024			$ change		% change		Impact of FX
	(in thousands, except percentages)
Revenue	$	1,210,638		$	1,232,871		$	(22,233)	(1.8)	%	0.2	%
Cost of revenue (excluding amortization of intangible assets)	842,050			836,876			5,174		0.6	%
Selling, general and administrative	125,563			111,338			14,225		12.8	%
Amortization of intangible assets	26,292			31,442			(5,150)		(16.4)	%
Operating income	$	216,733		$	253,215		$	(36,482)	(14.4)	%	1.9	%
Operating income % of revenue	17.9		%	20.5		%			(260) bps

DSA revenue decreased $22.2 million primarily due to lower volume driven by continued cautious client spending as a result of the current demand environment, partially offset by the effect of changes in foreign currency exchange rates.

DSA operating income decreased $36.5 million compared to the corresponding period in 2024. DSA operating income as a percentage of revenue for the six months ended June 28, 2025 was 17.9%, a decrease of 260 bps from 20.5% for the corresponding period in 2024. Operating income and operating income as a percentage of revenue decreased primarily due to the lower revenue described above, restructuring activities, including asset impairments and site consolidation charges, and certain third-party legal costs incurred in connection with the investigations by the U.S. government into the non-human primate supply chain compared to the corresponding period in 2024.

Manufacturing


	Six Months Ended
	June 28, 2025			June 29, 2024			$ change		% change		Impact of FX
	(in thousands, except percentages)
Revenue	$	379,321		$	377,510		$	1,811	0.5	%	0.1	%
Cost of revenue (excluding amortization of intangible assets)	217,023			218,378			(1,355)		(0.6)	%
Selling, general and administrative	66,448			66,660			(212)		(0.3)	%
Amortization of intangible assets	92,409			21,561			70,848		328.6	%
Operating income	$	3,441		$	70,911		$	(67,470)	(95.1)	%	(0.3)	%
Operating income % of revenue	0.9		%	18.8		%			(1,790) bps

Manufacturing revenue increased $1.8 million primarily due to an increase in our Microbial Solutions business driven by higher product revenue associated with endotoxin product revenue and identification services revenue and the effect of changes in foreign currency exchange rate; partially offset by decreased revenue in our Biologics Solutions business, driven by decreased demand for CDMO and Biologics Testing services.

Manufacturing operating income decreased $67.5 million compared to the corresponding period in 2024. Manufacturing operating income as a percentage of revenue for the six months ended June 28, 2025 was 0.9%, a decrease of 1790 bps from 18.8% for the corresponding period in 2024. Operating income and operating income as a percentage of revenue decreased primarily due to accelerated amortization expense as a result of a decrease in the remaining useful life of certain client relationships due to a loss of key customers within the CDMO business and restructuring activities, including asset impairments and site consolidation charges, compared to the corresponding period in 2024; partially offset by the higher revenue described above.

Unallocated Corporate


	Six Months Ended
	June 28, 2025			June 29, 2024			$ change		% change		Impact of FX
	(in thousands, except percentages)
Unallocated corporate	$	124,762		$	119,594		$	5,168	4.3	%	0.1	%
Unallocated corporate % of revenue	6.2		%	5.9		%			30 bps

Unallocated corporate costs consist of selling, general and administrative expenses that are not directly related or allocated to the reportable segments. The increase in unallocated corporate costs of $5.2 million, or 4.3%, compared to the corresponding

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

period in 2024 is primarily due to higher third-party legal and advisory costs incurred in connection with execution of the Cooperation Agreement. Costs as a percentage of revenue for the six months ended June 28, 2025 were 6.2%, an increase of 30 bps from 5.9% for the corresponding period in 2024.

Other Income (Expense)


	Six Months Ended
	June 28, 2025		June 29, 2024		$ change		% change
	(in thousands, except percentages)
Other income (expense):
Interest income	$	2,501	$	5,212	$	(2,711)	(52.0)	%
Interest expense	(57,851)		(67,770)		9,919		(14.6)	%
Other income (expense), net	(12,057)		3,593		(15,650)		(435.6)	%
Total other expense, net	$	(67,407)	$	(58,965)	$	(8,442)	14.3	%

Interest income for the six months ended June 28, 2025 was $2.5 million, a decrease of $2.7 million, or 52.0%, driven primarily from lower interest rates and interest earning asset balances.

Interest expense for the six months ended June 28, 2025 was $57.9 million, a decrease of $9.9 million, or 14.6%, compared to $67.8 million in the corresponding period in 2024 due primarily to lower average debt balances.

Other expense, net for the six months ended June 28, 2025 was $12.1 million compared to Other income, net of $3.6 million for the corresponding period in 2024 due primarily to venture capital investment losses of $9.0 million as compared to gains of $1.8 million in the corresponding period in 2024.

Income Taxes


	Six Months Ended
	June 28, 2025			June 29, 2024			$ change		% change
	(in thousands, except percentages)
Provision for income taxes	$	28,825		$	49,921		$	(21,096)	(42.3)	%
Effective tax rate	26.8		%	22.8		%			400 bps

Income tax expense for the six months ended June 28, 2025 was $28.8 million, a decrease of $21.1 million compared to $49.9 million for the corresponding period in 2024. Our effective tax rate was 26.8% for the six months ended June 28, 2025 compared to 22.8% for the corresponding period in 2024. The increase in our effective tax rate in the six months ended June 28, 2025 compared to the corresponding period in 2024 was primarily attributable to the tax effects from stock-based compensation deductions, as well as non-taxable remeasurement gains on a previous equity investment in Noveprim during the six months ended June 29, 2024.

Liquidity and Capital Resources

Liquidity and Cash Flows

In general we require cash to fund our working capital needs, capital expansion, acquisitions, debt payments, lease payments, venture capital investment, restructuring initiatives, and pension obligations. Our principal sources of liquidity have been our cash flows from operations supplemented by long-term borrowings. Based on our current business plan, we believe that our existing funds, when combined with cash generated from operations and our access to financing resources, are sufficient to fund our operations for the foreseeable future.

The following table presents our cash, cash equivalents and short-term investments:


	June 28, 2025		December 28, 2024
	(in thousands)
Cash and cash equivalents:
Held in U.S. entities	$	2,072	$	4,219
Held in non-U.S. entities	180,752		190,387
Total cash and cash equivalents	182,824		194,606
Short-term investments:
Held in non-U.S. entities	65		62
Total cash, cash equivalents and short-term investments	$	182,889	$	194,668

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

The following table presents our net cash provided by operating activities:


	Six Months Ended
	June 28, 2025		June 29, 2024
	(in thousands)
Net income	$	78,571	$	168,743
Adjustments to reconcile net income to net cash provided by operating activities	285,275		214,104
Changes in assets and liabilities	12,454		(59,424)
Net cash provided by operating activities	$	376,300	$	323,423

Net cash provided by cash flows from operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting our net income for (1) non-cash operating items such as depreciation and amortization, stock-based compensation, goodwill impairment, debt financing costs, deferred income taxes, write downs of inventories, provisions of credit losses, long-lived asset impairment changes, gains and/or losses on venture capital and strategic equity investments, gains and/or losses on divestitures, changes in fair value of contingent consideration, as well as (2) changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our results of operations.

The following table presents our net cash used in investing activities:


	Six Months Ended
	June 28, 2025		June 29, 2024
	(in thousands)
Capital expenditures	$	(94,622)	$	(118,630)
Investments, net	(5,984)		(23,179)
Proceeds from sale of businesses and assets, net	17,441		—
Acquisition of businesses and assets, net of cash acquired	$	—	$	(5,479)
Other, net	347		(370)
Net cash used in investing activities	$	(82,818)	$	(147,658)

Investing activities primarily consist of cash used to fund capital expenditures to support the growth of our business, purchases and sales of investments related to our venture capital and strategic equity investment portfolios, and asset and business acquisitions, periodically offset by cash from divestitures.

For the six months ended June 28, 2025, cash used in investing activities was primarily driven by capital expenditures partially offset by proceeds from divestitures of certain site and business assets. Capital expenditures decreased for the six months ended June 28, 2025 as compared to the same period in 2024, as a result of disciplined spend management in light of the global economic environment.

For the six months ended June 29, 2024, cash used in investing activities was primarily driven by capital expenditures to support the growth of the business, an immaterial asset acquisition, and investments in certain venture capital and strategic equity investments.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

The following table presents our net cash (used in) provided by financing activities:


	Six Months Ended
	June 28, 2025		June 29, 2024
	(in thousands)
Proceeds from long-term debt and revolving credit facility	$	963,363	$	741,200
Payments on long-term debt, revolving credit facility, and finance lease obligations	(887,706)		(987,344)
Proceeds from exercises of stock options	1		22,331
Purchase of treasury stock	(360,484)		(18,265)
Payment of contingent considerations	(21,822)		—
Purchase of remaining equity interest of other redeemable noncontrolling interest	(19,140)		(12,000)
Other, net	(6,458)		(13,434)
Net cash used in financing activities	$	(332,246)	$	(267,512)

Financing activities primarily consist of the proceeds and repayments of debt and certain equity related transactions including treasury stock purchases and employee stock option exercises.

For the six months ended June 28, 2025, net cash used in financing activities was primarily driven by the following activity:

•Net proceeds of $85.7 million from our Credit Facility

•Treasury stock purchases of $350.0 million associated with our stock repurchase program and $9.9 million due to the netting of common stock upon vesting of stock-based awards in order to satisfy individual statutory tax withholding requirements

•Payment of $21.8 million associated with contingent consideration related to the acquisition of Noveprim

•Payment of $19.1 million for the remaining 8% equity interest in Vital River

For the six months ended June 29, 2024, net cash provided by financing activities was primarily driven by the following activity:

•Net repayments of $252.4 million from our Credit Facility

•Net proceeds from exercises of employee stock options of $22.3 million

•Treasury stock purchases of $18.3 million made due to the netting of common stock upon vesting of stock-based awards in order to satisfy individual statutory tax withholding requirements

•Payment of $12.0 million for the remaining 10% equity interest in an other redeemable noncontrolling interest

Financing and Market Risk

We are exposed to market risk from changes in interest rates and currency exchange rates, which could affect our future results of operations and financial condition. We manage our exposure to these risks through our regular operating and financing activities.

Amounts outstanding under our Credit Facility and our Senior Notes were as follows:


	June 28, 2025		December 28, 2024
	(in thousands)
Revolving facility	$	813,002	$	714,948
4.25% Senior Notes due 2028	500,000		500,000
3.75% Senior Notes due 2029	500,000		500,000
4.00% Senior Notes due 2031	500,000		500,000
Total	$	2,313,002	$	2,214,948

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

The Credit Facility provides for up to $2.0 billion of multi-currency revolving credit and has a maturity date of December 2029, with no required scheduled payment before that date. The interest rates applicable to the revolving facility are equal to (A) for revolving loans denominated in U.S. dollars, at our option, either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50%, or (3) the one-month adjusted SOFR rate plus 1.0%) or the adjusted SOFR rate, (B) for revolving loans denominated in euros, the adjusted EURIBOR rate and (C) for revolving loans denominated in sterling, the daily simple SONIA rate, in each case, plus an interest rate margin based upon our leverage ratio.

Our off-balance sheet commitments related to our outstanding letters of credit as of June 28, 2025 and December 28, 2024 were $22.0 million and $22.4 million, respectively.

Foreign Currency Exchange Rate Risk

We operate on a global basis and have exposure to foreign currency exchange rate fluctuations for our financial position, results of operations, and cash flows.

While the financial results of our global activities are reported in U.S. dollars, our foreign subsidiaries typically conduct their operations in their respective local currency. The principal functional currencies of our foreign subsidiaries are the Euro, British Pound, Canadian Dollar, Chinese Yuan Renminbi, and Mauritian Rupee. During the six months ended June 28, 2025, the most significant drivers of foreign currency translation adjustment we recorded as part of Other comprehensive income (loss) were the Euro, British Pound, Canadian Dollar, Mauritian Rupee, and Hungarian Forint.

Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our financial position, results of operations, and cash flows. As the U.S. dollar strengthens against other currencies, the value of our non-U.S. revenue, expenses, assets, liabilities, and cash flows will generally decline when reported in U.S. dollars. The impact to net income as a result of a U.S. dollar strengthening will be partially mitigated by the value of non-U.S. expenses, which will decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue, expenses, assets, liabilities, and cash flows will generally increase when reported in U.S. dollars. For the six months ended June 28, 2025, our revenue would have decreased by $65.5 million, and our operating income would have decreased by $1.7 million, if the U.S. dollar exchange rate had strengthened by 10%, with all other variables held constant.

We attempt to minimize this exposure by using certain financial instruments in accordance with our overall risk management and our hedge policy. We do not enter into speculative derivative agreements.

Repurchases of Common Stock

On August 2, 2024, our Board of Directors approved a stock repurchase authorization of $1 billion. During the six months ended June 28, 2025, we repurchased 2.1 million shares of common stock for $350.0 million under the new stock repurchase program. As of June 28, 2025, we had $549.3 million remaining on the current authorized stock repurchase program.

Additionally, our stock-based compensation plans permit the netting of common stock upon vesting of restricted stock, restricted stock units, and performance share units in order to satisfy individual statutory tax withholding requirements. During the six months ended June 28, 2025, we acquired 0.1 million shares for $9.9 million through such netting.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements prepared in accordance with generally accepted accounting principles in the U.S. The preparation of these financial statements requires us to make certain estimates and assumptions that may affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses during the reported periods, and the related disclosures. These estimates and assumptions are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on our historical experience, trends in the industry, and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from our estimates under different assumptions or conditions.

We believe that the application of our accounting policies, each of which require significant judgments and estimates on the part of management, are the most critical to aid in fully understanding and evaluating our reported financial results. Our significant accounting policies are more fully described in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for fiscal year 2024 as filed with the SEC on February 19, 2025. There have been no changes in the Company’s critical accounting policies during the six months ended June 28, 2025.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements please refer to Note 1, “Basis of Presentation,” in this Quarterly Report on Form 10-Q. Other than as discussed in Note 1, “Basis of Presentation,” we did not adopt any other new accounting pronouncements during the six months ended June 28, 2025 that had a significant effect on our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

The Company’s exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from its exposure discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2024 as filed with the SEC on February 19, 2025. Our interest rate and currency exchange rate risks are fully described in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources” of our Annual Report on Form 10-K for fiscal year 2024 and in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources” herein.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Based on their evaluation, required by paragraph (b) of Rules 13a-15 or 15d-15, promulgated by the Securities Exchange Act of 1934, as amended (Exchange Act), the Company’s principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, are effective, at a reasonable assurance level, as of June 28, 2025, to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgement in evaluating the benefits of our controls and procedures relative to their costs.

(b) Changes in Internal Controls Over Financial Reporting

There were no material changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of the Exchange Act Rules 13a-15 or 15d-15 that occurred during the quarter ended June 28, 2025 that materially affected, or were reasonably likely to materially affect, the Company’s internal control over financial reporting.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

On February 17, 2023, the Company received a grand jury subpoena requesting certain documents related to an investigation by the U.S. Department of Justice (DOJ) and the U.S. Fish and Wildlife Service (USFWS) into the Company’s conduct regarding several shipments of non-human primates from Cambodia in late 2022 and early 2023 (the NHP Shipments). The DOJ also undertook a parallel civil investigation related to the NHP Shipments. As previously disclosed, the Company continued to care for the NHP Shipments during the pendency of the DOJ investigations. In July 2025, the Company was informed that USFWS had determined to clear the NHP Shipments for legal entry into the United States. Furthermore, in recent weeks the Company has been advised by the DOJ that both the grand jury investigation and the parallel civil investigation had been closed.

On May 16, 2023, the Company received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena and additional inquiries, primarily related to the sourcing of non-human primates and related disclosures, and the Company is cooperating with the requests. The Company’s Audit Committee has retained counsel to conduct an independent investigation into certain issues raised in the investigations, and that work is ongoing. We are not able to predict what action, if any, might be taken in the future by the SEC. The SEC has not provided the Company with any specific timeline or indication as to when the investigation will be concluded or resolved. The Company cannot predict the timing, outcome or possible impact of the investigation, including without limitation any potential fines, penalties or liabilities.

A putative securities class action (Securities Class Action) was filed on May 19, 2023 against the Company and a number of its current/former officers in the United States District Court for the District of Massachusetts. On August 31, 2023, the court appointed the State Teachers Retirement System of Ohio as lead plaintiff. An amended complaint was filed on November 14, 2023 that, among other things, included only James Foster, the Chief Executive Officer and David R. Smith, the former Chief Financial Officer as defendants along with the Company. The amended complaint asserts claims under §§ 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act) on behalf of a putative class of purchasers of Company securities from May 5, 2020 through February 21, 2023, alleging that certain of the Company’s disclosures about its practices with respect to the importation of non-human primates made during the putative class period were materially false or misleading. On July 1, 2024, the court dismissed the complaint, denied the plaintiff’s informal request for leave to amend, and entered judgment for defendants. On July 30, the plaintiff filed a notice of appeal in the United States Court of Appeals for the First Circuit. Oral arguments took place on May 5, 2025. While the Company cannot predict the final outcome of this matter, it believes the class action to be without merit and plans to vigorously defend against it. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with this matter.

On November 8, 2023, a stockholder filed a derivative lawsuit in the U.S. District Court of the District of Delaware asserting claims on the Company’s behalf against the members of the Company’s Board of Directors and certain of the Company’s current/former officers (James Foster, the Chief Executive Officer; David R. Smith, the former Chief Financial Officer; and Flavia Pease, the current Chief Financial Officer). The complaint alleges that the defendants breached their fiduciary duties to the Company and its stockholders because certain of the Company’s disclosures about its practices with respect to the importation of non-human primates were materially false or misleading. The complaint also alleges that the defendants breached their fiduciary duties by causing the Company to fail to maintain adequate internal controls over securities disclosure and compliance with applicable law and by failing to comply with the company’s Code of Business Conduct and Ethics. On August 2, 2024, a different stockholder filed a lawsuit in the U.S. District Court of Delaware asserting similar derivative claims on the Company’s behalf against members of the Company’s current and former Board of Directors and the same current/former officers based on similar allegations of purportedly misleading disclosures and non-compliance with legal rules and ethics standards in respect of the importation of non-human primates, as well as insider-trading claims against certain of the defendants. Both of these lawsuits are currently stayed by agreement of the parties pending further developments in the Securities Class Action pending in the United States Court of Appeals for the First Circuit. While the Company cannot predict the outcome of these matters, it believes the derivative lawsuits to be without merit and plans to vigorously defend against them. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with these matters.

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for fiscal year 2024, which could materially affect our business, financial condition, and/or future results. The risks described in our Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results. There have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for fiscal year 2024 as filed with the SEC on February 19, 2025, except as disclosed below.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition can have an adverse effect on our business and financial statements.

Significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition, including laws and policies in areas such as trade, manufacturing, government purchasing, healthcare, intellectual property, regulatory enforcement and investment/development, can adversely affect our business and financial statements. The U.S. has experienced a rapid increase in new government regulations, including tariffs and proposed tariffs on imports from a wide range of markets and geographies, including some in which we operate. These tariffs/proposed tariffs have prompted retaliatory tariffs by a number of countries and a cycle of retaliatory tariffs by both the U.S. and other countries. In early April 2025, actions were taken by the U.S. and certain other countries to delay the effective date of certain of these tariffs, but as of the date of this report a number of new tariffs remain in effect, including significant tariffs between the U.S. and countries from which we obtain significant supply, such as Vietnam, Mauritius, and China. Collectively, this may adversely impact our operating margin and results of operations, for example, our costs and expenses related to our business activities and those of our customers and suppliers; demand for our products and our competitive positioning; the availability to us of certain products in certain countries; and our supply chain operations. Please see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for further discussion of the impact of these tariffs. Though the risks identified above in certain cases have already adversely impacted part of our business, the full impact of these tariffs and other actions on the Company and on our business partners remains highly uncertain and subject to rapid change.

A reduction or delay in government funding of R&D may adversely affect our business.

A portion of revenue, predominantly in our RMS segment, is derived from clients at academic institutions and research laboratories whose funding is partially dependent on both the level and timing of funding from government sources such as the U.S. National Institutes of Health (NIH) and similar domestic and international agencies, which can be difficult to forecast. We also sell directly to the NIH and these other agencies. Government funding of R&D is subject to the political process, which is inherently fluid and unpredictable. For example, the NIH announced on February 7, 2025, a policy significantly reducing research grants by limiting payments for indirect overhead. While, as of the date of this filing, the order is subject to a preliminary injunction, there can be no assurance that a permanent injunction will be granted or that other adverse actions will not be taken. Our revenue may be adversely affected if our clients delay purchases as a result of uncertainties surrounding the approval of government budget proposals, included reduced allocations to government agencies that fund R&D activities. Government proposals to reduce or eliminate budgetary deficits have sometimes included reduced allocations to the NIH and other government agencies that fund R&D activities, or NIH funding may not be directed towards projects and studies that require the use of our products and services, both of which could adversely affect our business and our financial results.

Changes in government regulation or in practices relating to the pharmaceutical or biotechnology industries, including potential healthcare reform, could decrease the need for the services we provide.

Governmental agencies throughout the world strictly regulate the drug development process. Our business involves helping our customers navigate these regulatory processes. Accordingly, many regulations, and often new regulations, are expected to result in higher regulatory standards and often additional revenues for companies that service these industries. However, some changes in regulations, such as a relaxation in regulatory requirements or the introduction of streamlined or expedited drug approval procedures, or an increase in regulatory requirements that we have difficulty satisfying or that make our services less competitive, could eliminate or substantially reduce the demand for our services.

For example: in December 2022, the FDA Modernization Act 2.0 was passed, which clarifies methods manufacturers and sponsors can use to investigate the safety and efficacy of a drug; and in April 2025 the FDA announced its intention to reduce animal testing in preclinical safety studies with scientifically validated cell-based and new approach methodologies (NAMs), such as organ-on-a-chip systems, computational modeling, and advanced in vitro assays. Eliminating the use of animals in research may have material adverse effects on our business, results of operations, or financial condition. While there have been significant advancements in the development of alternative methods, the complete elimination of animals in research will be a gradual process that may take many years to achieve. While we are committed to working with the industry to support development and to provide the best translational models to supplement or replace traditional models as part of our Replacement, Reduction, and Refinement (3Rs) initiative and our Alternative Methods Advancement Project (AMAP), the use of animals in research is highly regulated and proposed changes to current regulations will need to be carefully evaluated to ensure that they do not compromise the safety and efficacy of new drugs and medical treatments.

Although we believe we are currently in compliance in all material respects with applicable national, regional and local laws, as well as other accepted guidance used by oversight bodies (including the USDA, the standards set by the International Air Transport Association, the Convention on International Trade in Endangered Species of Wild Fauna and Flora, USFWS, The Centers for Disease Control, the Department of Transportation, the Department of State, the office of Laboratory Animal Welfare of NIH, the Drug Enforcement Agency, as well as numerous other oversight agencies in the jurisdictions in which we operate), failure to comply could subject us to denial of the right to conduct business, fines, criminal penalties and other

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

enforcement actions. For additional discussion of the factors specifically affecting our non-human primates including related oversight trade compliance agencies, please see the sections entitled “Item 1A. Risk Factors – Industry Risk Factors - Several of our product and service offerings, including our non-human primate supply, are dependent on a limited source of supply that, when interrupted, adversely affects our business”, included within our Annual Report on Form 10-K for fiscal year 2024 as filed with the SEC on February 19, 2025 and “Item 1. Legal Proceedings” above. In addition, if regulatory authorities were to mandate a significant reduction in safety assessment procedures that utilize research animals (as has been advocated by certain groups), certain segments of our business could be materially adversely affected.

Implementation of healthcare reform legislation, such as certain provisions of the Inflation Reduction Act, may have certain benefits, but also may contain costs that could limit the profits that can be made from the development of new drugs. This could adversely affect R&D expenditures by pharmaceutical and biotechnology companies, which could in turn decrease the business opportunities available to us both in the U.S. and abroad. In addition, new laws or regulations may create a risk of liability, increase our costs or limit our service offerings. Furthermore, if health insurers were to change their practices with respect to reimbursements for pharmaceutical products, our clients may spend less or reduce their growth in spending on R&D.

While it is not possible to predict whether and when any such changes will occur, changes at the local, state or federal level, or in laws and regulations in effect in foreign jurisdictions in which we operate or have business relationships, may significantly impact our domestic and foreign businesses and/or those of our clients. Furthermore, modifications to international trade policy, public company reporting requirements, environmental regulation and antitrust enforcement may have a materially adverse impact on us, our suppliers or our clients.

New technologies may be developed, validated and increasingly used in biomedical research, which could reduce demand for some of our products and services.

The scientific community continues to develop NAMs, which do not involve working with animal models and are designed to increase the translation from findings in early-stage discovery and pre-clinical studies to human studies, and vice-versa. As these methods continue to advance, they may supplement, and in some cases possibly replace or supplant methodologies that are currently in use, such as the use of traditional living animals in biomedical research. For example, in April 2025, the FDA announced its intention to reduce animal testing in preclinical safety studies with NAMs, such as organ-on-a-chip systems, computational modeling, and advanced in vitro assays. In addition, technological improvements, such as imaging and other translational biomarker technologies, could impact demand for animal research models. Further, manufacturers, including Charles River, have recently introduced recombinant versions of LAL, which has been historically derived from live animals. It is our strategy to explore new technologies to refine and potentially reduce the use of animal models and animal derived products as new in vitro and in silico methods become available and synthetically-manufactured products become validated with sufficient data to ensure public safety. For information regarding our efforts to support development and to provide the best translational models to supplement or replace traditional models, see “Our Strategy” included within our Annual Report on Form 10-K for fiscal year 2024 as filed with the SEC on February 19, 2025. However, we may not be able to develop new products, inputs or processes effectively or in a timely manner to replace any lost sales. Lastly, other companies or entities may develop research models, inputs or processes with characteristics different from those that we produce, and that may be viewed as more desirable by some of our clients.

Our quarterly operating results may vary, which could negatively affect the market price of our common stock.

Our results of operations in any quarter may vary from quarter to quarter and are influenced by the risks discussed above, as well as: changes in the general global economy; changes in the mix of our products and services; changes in government regulation or in practices related to the pharmaceutical or biotechnology industries, including with respect to the use of NAMs; cyclical buying patterns of our clients; the financial performance of our strategic and venture capital investments; certain acquisition-related adjustments, including change in fair value of contingent payments both receivable from or payable to counterparties; and the occasional extra week (“53rd week”) that we recognize in a fiscal year (and fourth fiscal quarter thereof), including 2022, due to our fiscal year ending on the last Saturday in December. We believe that operating results for any particular quarter are not necessarily a meaningful indication of future results. Nonetheless, fluctuations in our quarterly operating results could negatively affect the market price of our common stock.

Our review of potential strategic alternatives may not result in an executed or consummated transaction or other strategic alternative, and the process of reviewing strategic alternatives or the outcome could adversely affect our business.

On May 6, 2025, in connection with a Cooperation Agreement entered into with a large shareholder of the Company, we agreed, among other things, to have the Strategic Partnership and Capital Allocation Committee of our Board of Directors oversee and direct a comprehensive strategic review and evaluation of the Company’s business and prospects, including an examination of various alternatives to enhance long-term stockholder value. There is no assurance that the process will result in the approval or completion of any specific transaction or outcome. Further, there is no guarantee that any transaction resulting from the strategic review will ultimately benefit our stockholders.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

The process of reviewing potential strategic and operational alternatives is time consuming and costly and may divert management’s attention. It may also be disruptive to our business operations and long-term planning, which may cause concern to our current or potential investors, customers, employees, strategic partners, vendors and other stakeholders and may have a material impact on our operating results or result in increased volatility in our stock price.

Any potential transaction or other strategic alternative would be dependent on a number of factors that may be beyond our control, including, among other things, market conditions, industry trends, regulatory approvals, and the availability of financing for a potential transaction on favorable terms. There can be no assurance that any potential transaction or other strategic alternative will be successfully implemented, achieve the intended benefits or provide greater value to our stockholders than that reflected in the current price of our common stock. Until the review process is concluded, perceived uncertainties related to our future may result in the loss of potential business opportunities, volatility in the market price of our common stock and difficulty attracting and retaining qualified talent and business partners.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information relating to the purchases of shares of our common stock during the three months ended June 28, 2025.


	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs
					(in thousands)
March 30, 2025 to April 26, 2025	—	$	—	—	$	549,285
April 27, 2025 to May 24, 2025	926	116.96		—	549,285
May 25, 2025 to June 28, 2025	48,782	136.47		—	549,285
Total	49,708			—

On August 2, 2024, our Board of Directors has authorized, in aggregate, a stock repurchase authorization of $1 billion. During the three months ended June 28, 2025, we did not repurchase any shares of common stock under our stock repurchase program or in open market trading. As of June 28, 2025, we had $549.3 million remaining on the authorized stock repurchase program.

Additionally, our stock-based compensation plans permit the netting of common stock upon vesting of restricted stock units, and performance share units in order to satisfy individual statutory tax withholding requirements.

Item 5. Other Information

During the quarter ended June 28, 2025, none of our officers or directors or any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Item 6. Exhibits

(a) Exhibits

Description of Exhibits

Filed with this Form 10-Q

Incorporation by Reference

Form

Filing Date

Exhibit No.

10.1+

Amendment to the Amended and Restated Employment Agreement by and between James C. Foster and Charles River International, Inc., dated May 20, 2025

10.2

Cooperation Agreement, by and among the Company and Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P., dated as of May 6, 2025

8-K

May 7, 2025

10.1

31.1

Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer

31.2

Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer

32.1+

Certification of the Principal Executive Officer and the Principal Financial Officer required by Rule 13a-14(a) of 15d-14(a) of the Exchange Act

101.INS

eXtensible Business Reporting Language (XBRL) Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Calculation Linkbase Document

101.DEF

XBRL Taxonomy Definition Linkbase Document

101.LAB

XBRL Taxonomy Label Linkbase Document

101.PRE

XBRL Taxonomy Presentation Linkbase Document

+ Furnished herein.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


						CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

			August 6, 2025			/s/ JAMES C. FOSTER
						James C. Foster Chairman, President and Chief Executive Officer

			August 6, 2025			/s/ FLAVIA H. PEASE
						Flavia H. Pease Corporate Executive Vice President and Chief Financial Officer

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. - Quarter Report: 2025 June (Form 10-Q)

Similar companies